Abstract 1676P
Background
Breast cancer (BC) survivors face many problems regarding sex. A range of medical treatments targeted to breast cancer patients leave behind large side effects that can negatively influence their sex life and change their body image, their self-esteem and their confidence. Most Tunisian Breast cancer survivors are reluctant to discuss their sexual problems with their doctors. Thus, their troubled sex life remains hidden. The aim of our study was to identify those sexual difficulties and to address the problems our patients are facing.
Methods
Patients diagnosed and treated for BC at the medical oncology department with active sex life prior to diagnosis were asked to complete a questionnaire from January to March 2023. The survey’s aim is to highlight the underlying problems breast cancer survivors are confronting and to help them lead a healthy sex life. One hundred women participated in our study.
Results
The medium age for our patients was 52.24 years. In our population, 52% of the women underwent radical mastectomy. All of our patients underwent radiotherapy and 88% underwent chemotherapy. Before BC diagnosis, patients who rarely had sex represent 28% of the women, those who had sex once a week represent 52% and those who had sex on a regular basis (more than once a week) represented 20% of the population. After surgery, 72% of our patients reported rarely having sexual relationships (less than once a month). Only 16% of our patients reported having intercourse once a week. As for patients who maintained a regular sex life after surgery (more than once a week), they represent 12% of the population. This drop in the frequency of sexual relationship is linked to multiple causes: body dysmorphia and failure to accept body changes 76%, lower libido in 80%; less vaginal sensation in 64% and vaginal dryness in 84%. Dyspareunia was experienced by 60% compared 36% before surgery. None of the women sought medical consult. No medication nor lubrification was used by the patients to improve their symptoms.
Conclusions
Breast cancer survivors are reluctant to discuss their sexuality and the problems they are facing after surgery. Even though patients don’t ask for help, it is our duty as clinicians to identify the problems and help our patients to receive the adequate treatment and advice.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1699P - Impact of Latino ethnicity on the gut microbiome and response to immune checkpoint inhibition (ICI) with CBM588 in patients (pts) with metastatic renal cell cancer (mRCC)
Presenter: Regina Barragan-Carrillo
Session: Poster session 11
1700P - Impact of sarcomatoid (S) and rhabdoid (R) components (comp.) on the efficacy of nivolumab (N) +/- ipilimumab (I) in the first-line (L1) treatment of metastatic clear cell renal cell carcinoma (mRCC) in the randomized phase II BIONIKK trial
Presenter: Yann-Alexandre Vano
Session: Poster session 11
1701P - NEOTAX: A phase II trial of neoadjuvant toripalimab plus axitinib for clear cell renal cell carcinoma with inferior vena cava tumor thrombus
Presenter: Liangyou Gu
Session: Poster session 11
1702P - Updated results of phase II study of cabozantinib (Cabo) with nivolumab (Nivo) and ipilimumab (Ipi) in advanced renal cell carcinoma with divergent histologies (RCCdh)
Presenter: Bradley McGregor
Session: Poster session 11
1703P - Updated overall survival in patients with prior checkpoint inhibitor (CPI) therapy in the phase III TIVO-3 study
Presenter: Miguel Zugman
Session: Poster session 11
1704P - Potential surrogate endpoints for overall survival (OS) in immunotherapy (IO)-treated metastatic renal cell carcinoma (mRCC): An International Metastatic Database Consortium (IMDC) study
Presenter: Renee Saliby
Session: Poster session 11
1705P - Association between baseline radiological tumor burden (BRTB) and outcomes in metastatic clear cell renal cell carcinoma (mccRCC) treated with first line (1L) immunotherapy (IO)-based regimens
Presenter: Rashad Nawfal
Session: Poster session 11
1707P - A plasma proteomic based algorithm is associated with prognosis in renal cell carcinoma
Presenter: Eddy Saad
Session: Poster session 11
1708P - The clinical value of tumor-informed minimal residual disease detection in renal cell carcinoma
Presenter: linhui wang
Session: Poster session 11